Everolimus plus endocrine therapy beyond CDK4/6 inhibitors progression for HR+ /HER2− advanced breast cancer: a real-world evidence cohortRodrigo Sánchez-Bayona, Miguel Martín, Alfonso López de et al.|Breast Cancer Research and Treatment|2024Cited by 21
Outcomes and endpoints of relevance in gynecologic cancer clinical trialsAinhoa Madariaga, Antonio González-Martı́n, Rodrigo Sánchez-Bayona et al.|International Journal of Gynecological Cancer|2023Cited by 11
Efficacy outcomes of CDK4/6 inhibitors in combination with endocrine therapy treatment in hormone receptor-positive/HER2-negative advanced breast cancer according to PAM50 intrinsic subtype: Primary results of SOLTI-1801 CDK-PREDICT studyPablo Tolosa, Eva Ciruelos, Laura Lema et al.|European Journal of Cancer|2025Cited by 10
Vitamin D and Risk of Obesity-Related Cancers: Results from the SUN (‘Seguimiento Universidad de Navarra’) ProjectRodrigo Sánchez-Bayona, Estefanía Toledo, Maira Bes‐Rastrollo et al.|Nutrients|2022Cited by 7
HER2DX ERBB2 mRNA score in first-line advanced HER2-positive breast cancer treated with chemotherapy, trastuzumab, and pertuzumabRodrigo Sánchez-Bayona, Aleix Prat, Olga Martínez‐Sáez et al.|npj Breast Cancer|2025Cited by 6